Singapore-based firm to start human trials for Covid-19 treatment
Team Udayavani, Jun 12, 2020, 11:02 AM IST
Tychan, Singaporean biotechnology firm, will begin human clinical trials next week for a potential monoclonal antibody treatment for Covid-19
The first phase of the trial will be conducted on healthy volunteers to determine the safety and tolerability of TY027, a monoclonal antibody or immune system protein that specifically targets the virus that causes Covid-19.
TY027 is being explored for its ability to slow down the progression of Covid-19 and speed up recovery, and its potential to provide temporary protection against infection
It is said that if phase one is successful, Tychan will seek approval for the antibody to be administered to a larger population of volunteer patients in subsequent trials.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
China says talks on Tibet only with Dalai Lama’s representatives; rules out dialogue on autonomy
Indian-origin man shot, killed by San Antonio police amid attempts to apprehend him
2 Indian restaurants in Colorado duped investors of USD 380K: Officials
WATCH: 5 runaway military horses cause mayhem in London
Don’t blame Dubai’s freak rain on cloud seeding
MUST WATCH
Latest Additions
Patanjali Foods to evaluate proposal to buy Patanjali Ayurved’s non-food business
Congress to discuss candidates for Amethi, Raebareli seats on Saturday
BJP’s CT Ravi Booked for Promoting Hatred and Enmity Through Social Media Post
Elections held in 14 LS segments in Karnataka, voter turnout nearly 64 per cent till 5 pm
‘PM is scared, may even shed tears on stage’: Rahul Gandhi’s fresh salvo at Modi